Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCash Due from BankCommon EquityFed Funds SoldGoodwillGoodwill & IntangiblesIntangiblesInterest DepositsLiabilities and Shareholders EquityLoans - GrossLoans - Loss AllowanceLoans - NetLong-Term Deferred TaxNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Retained EarningsSecurities - Held-to-maturitySecurities - TradableShareholder's EquityTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capital Bancorp (CBNK) Cash & Equivalents: 2017-2025

Historic Cash & Equivalents for Capital Bancorp (CBNK) over the last 7 years, with Sep 2025 value amounting to $188.9 million.

  • Capital Bancorp's Cash & Equivalents rose 20.52% to $188.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $188.9 million, marking a year-over-year increase of 20.52%. This contributed to the annual value of $205.3 million for FY2024, which is 280.50% up from last year.
  • Per Capital Bancorp's latest filing, its Cash & Equivalents stood at $188.9 million for Q3 2025, which was down 31.22% from $274.6 million recorded in Q2 2025.
  • Capital Bancorp's Cash & Equivalents' 5-year high stood at $324.0 million during Q3 2021, with a 5-year trough of $37.1 million in Q3 2022.
  • In the last 3 years, Capital Bancorp's Cash & Equivalents had a median value of $146.2 million in 2023 and averaged $163.7 million.
  • Per our database at Business Quant, Capital Bancorp's Cash & Equivalents plummeted by 88.56% in 2022 and then surged by 294.34% in 2023.
  • Over the past 5 years, Capital Bancorp's Cash & Equivalents (Quarterly) stood at $183.4 million in 2021, then plummeted by 56.15% to $80.4 million in 2022, then slumped by 32.89% to $54.0 million in 2023, then surged by 280.50% to $205.3 million in 2024, then increased by 20.52% to $188.9 million in 2025.
  • Its Cash & Equivalents was $188.9 million in Q3 2025, compared to $274.6 million in Q2 2025 and $294.0 million in Q1 2025.